Orzaks Pharma's Asian Expansion: Targeting a Slice of India's $11 Billion Supplement Market

Orzaks Ilac ve Kimya Sanayi Ticaret A.S. (ORZAX), one of the significant players in the Turkish pharmaceutical sector, is anchoring its presence in the Asia-Pacific region by establishing a subsidiary in India, aiming to capitalize on the region's rapidly rising demand for supplements and cosmetics. To respond to this surge, the company has incorporated a new subsidiary in the Delhi region, in which it holds a 99.99% stake.

Strategic Roots in India: New Subsidiary Established

To deepen its operational reach in international markets, Orzaks Ilac has officially incorporated Orzax Life Sciences Private Limited. This move is viewed not just as an export-oriented strategy, but as part of a growth vision involving direct local production and marketing.

■Company Title: Orzax Life Sciences Private Limited

■Headquarters: Delhi State, India

■Registered Capital: 100,000 Indian Rupees

■Investment by Orzaks: 99,990 Indian Rupees (9,999 shares)

■Ownership Ratio: 99.99%

■Authorized Representative: Selman Alimoğlu (Company Director)

Billion-Dollar Target Markets

According to data disclosed by the company management to the Public Disclosure Platform (KAP), the potential offered by the Indian market is not limited to current size but promises a sustainable upward trend. Particularly with the expansion of the middle class and rising health awareness, explosive growth is forecast in two main sectors.

■Supplement Market: Having reached 5.2 billion USD in 2024 and 5.8 billion USD in 2025, the market is expected to reach 6.5 billion USD in 2026 and 11 billion USD by 2030.

■Beauty and Cosmetic Market: The sector, which reached a size of 27 billion USD as of 2025, is projected to rise to levels approaching 39 billion USD by 2030.

■Strategic Position: India's central role in global raw material supply will provide the company with cost advantages and logistical efficiency.

Supply Chain and Operational Edge

One of the core motivations behind this strategic investment is integrating the power of India's global raw material supply into its own operations. Orzaks Ilac plans to become more resilient against fragilities in the global supply chain while optimizing production costs through this move. The localization strategy aims to increase the brand's market share in the region while also accelerating exports to the Asia-Pacific region.

Although this move by Orzaks Ilac (ORZAX) may not bring immediate massive cash flow to the balance sheet, it acts as a catalyst that significantly raises the "Compound Annual Growth Rate" (CAGR) potential in the company's growth story. From a technical perspective, this represents a structural transformation that will positively shift the long-term perception of the stock in line with 2030 targets. Entering India's 11 billion USD supplement market can be read as a critical Fibonacci correction and the start of a rising wave that evolves ORZAX from a local manufacturer into a global player. Investors should note that such geographic expansions typically reflect in prices through operational efficiency and margin expansion.